Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes

Por Faiman, Beth, Valent, Jason
Publicado no Blood Lymphat Cancer (2016)

Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed

Por Tageja, Nishant, Racovan, Marius, Valent, Jason, Zonder, Jeffrey
Publicado em 2010

Solitary extramedullary plasmacytoma of the penis

Por Scarberry, Kyle, Jegalian, Armin, Valent, Jason, Wood, Hadley M.
Publicado em 2014

A 70-Year-Old Man With Large Cervical and Mediastinal Lymphadenopathies

Por Narechania, Shraddha, Valent, Jason, Farver, Carol, Tonelli, Adriano R.
Publicado no Chest (2015)

Patient-reported outcomes in systemic AL amyloidosis with Functional Assessment of Cancer Therapy-General (FACT-G) and Patient-Reported Outcomes Measurement Information System-Glob...

Por Chakraborty, Rajshekhar, Rybicki, Lisa, Tomer, Jacqulyn, Samaras, Christy J., Faiman, Beth M., Valent, Jason, Majhail, Navneet S.
Publicado no Leuk Lymphoma (2019)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

Por Sidana, Surbhi, Narkhede, Mayur, Elson, Paul, Hastings, Debbie, Faiman, Beth, Valent, Jason, Samaras, Christy, Hamilton, Kimberly, Liu, Hien K., Smith, Mitchell R., Reu, Frederic J.
Publicado no PLoS One (2017)

Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma

Por Bhutani, Divaya, Zonder, Jeffrey, Valent, Jason, Tageja, Nishant, Ayash, Lois, Deol, Abhinav, Al-Kadhimi, Zaid, Abrams, Judith, Lum, Lawrence, Ratanatharathorn, Voravit, Uberti, Joseph, Abidi, Muneer H.
Publicado em 2013

Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development

Por Iftikhar, Ahmad, Hassan, Hamza, Iftikhar, Nimra, Mushtaq, Adeela, Sohail, Atif, Rosko, Nathaniel, Chakraborty, Rajshekhar, Razzaq, Faryal, Sandeep, Sonia, Valent, Jason Neil, Kanate, Abraham Sebastian, Anwer, Faiz
Publicado no Antibodies (Basel) (2019)

Future of personalized therapy targeting aberrant signaling pathways in multiple myeloma

Por Anwer, Faiz, Gee, Kevin Mathew, Iftikhar, Ahmad, Baig, Mirza, Russ, Atlantis Dawn, Saeed, Sabina, Zar, Muhammad Abu, Razzaq, Faryal, Carew, Jennifer, Nawrocki, Steffan, Al-Katab, Hussam, Cavalcante, Nadia Nunes, McBride, Ali, Valent, Jason, Samaras, Christy
Publicado no Clin Lymphoma Myeloma Leuk (2019)

Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma

Por Chari, Ajai, Cornell, Robert F., Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey V., Niesvizky, Ruben, Lunning, Matthew, Usmani, Saad Z., Anderson, Larry D., Chhabra, Saurabh, Girnius, Saulius, Shustik, Chaim, Stuart, Robert, Lee, Yihua, Salman, Zeena, Liu, Emily, Valent, Jason
Publicado no Hematol Oncol (2020)

Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma

Por Hu, Yi, Liu, Huimin, Fang, Chuanfeng, Li, Chen, Xhyliu, Fjorela, Dysert, Hayley, Bodo, Juraj, Habermehl, Gabriel, Russell, Benjamin E., Li, Wenjun, Chappell, Marcia, Jiang, Xiaofeng, Ondrejka, Sarah L., Hsi, Eric D., Maciejewski, Jaroslaw P., Yi, Qing, Anderson, Kenneth C., Munshi, Nikhil C., Ao, Geyou, Valent, Jason N., Lin, Jianhong, Zhao, Jianjun
Publicado no Cancer Res (2020)